BMY Quote, Financials, Valuation and Earnings

Gilead Sciences has a net margin of 21.93% compared to Bristol-Myers Squibb's net margin of 19.72%. Bristol-Myers Squibb's return on equity of 32.01% beat Gilead Sciences's return on equity of 32.29%.

Bristol-Myers Squibb has a consensus price target of $57.01, signalling upside risk potential of 20.85%. On the other hand Gilead Sciences has an analysts' consensus of $116.85 which suggests that it could grow by 6.37%. Given that Bristol-Myers Squibb has higher upside potential than Gilead Sciences, analysts believe Bristol-Myers Squibb is more attractive than Gilead Sciences.

Bristol-Myers Squibb has a beta of 0.363, which suggesting that the stock is 63.75% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.290, suggesting its less volatile than the S&P 500 by 71.014%.

Bristol-Myers Squibb has a quarterly dividend of $0.62 per share corresponding to a yield of 5.22%. Gilead Sciences offers a yield of 2.84% to investors and pays a quarterly dividend of $0.79 per share. Bristol-Myers Squibb pays -54.35% of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend.

Bristol-Myers Squibb quarterly revenues are $11.2B, which are larger than Gilead Sciences quarterly revenues of $6.7B. Bristol-Myers Squibb's net income of $2.5B is higher than Gilead Sciences's net income of $1.3B. Notably, Bristol-Myers Squibb's price-to-earnings ratio is 17.67x while Gilead Sciences's PE ratio is 23.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bristol-Myers Squibb is 2.01x versus 4.82x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 21.93% compared to Bristol-Myers Squibb's net margin of 23.32%. Bristol-Myers Squibb's return on equity of 32.01% beat Johnson & Johnson's return on equity of 30.18%.

Bristol-Myers Squibb has a consensus price target of $57.01, signalling upside risk potential of 20.85%. On the other hand Johnson & Johnson has an analysts' consensus of $170.92 which suggests that it could grow by 3.36%. Given that Bristol-Myers Squibb has higher upside potential than Johnson & Johnson, analysts believe Bristol-Myers Squibb is more attractive than Johnson & Johnson.

Bristol-Myers Squibb has a beta of 0.363, which suggesting that the stock is 63.75% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.414, suggesting its less volatile than the S&P 500 by 58.579%.

Bristol-Myers Squibb has a quarterly dividend of $0.62 per share corresponding to a yield of 5.22%. Johnson & Johnson offers a yield of 3.05% to investors and pays a quarterly dividend of $1.30 per share. Bristol-Myers Squibb pays -54.35% of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bristol-Myers Squibb quarterly revenues are $11.2B, which are smaller than Johnson & Johnson quarterly revenues of $23.7B. Bristol-Myers Squibb's net income of $2.5B is lower than Johnson & Johnson's net income of $5.5B. Notably, Bristol-Myers Squibb's price-to-earnings ratio is 17.67x while Johnson & Johnson's PE ratio is 17.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bristol-Myers Squibb is 2.01x versus 4.41x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 21.93% compared to Bristol-Myers Squibb's net margin of 21.68%. Bristol-Myers Squibb's return on equity of 32.01% beat Eli Lilly and's return on equity of 78.25%.

Bristol-Myers Squibb has a consensus price target of $57.01, signalling upside risk potential of 20.85%. On the other hand Eli Lilly and has an analysts' consensus of $952.27 which suggests that it could grow by 20.57%. Given that Bristol-Myers Squibb has higher upside potential than Eli Lilly and, analysts believe Bristol-Myers Squibb is more attractive than Eli Lilly and.

Bristol-Myers Squibb has a beta of 0.363, which suggesting that the stock is 63.75% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.405, suggesting its less volatile than the S&P 500 by 59.528%.

Bristol-Myers Squibb has a quarterly dividend of $0.62 per share corresponding to a yield of 5.22%. Eli Lilly and offers a yield of 0.71% to investors and pays a quarterly dividend of $1.50 per share. Bristol-Myers Squibb pays -54.35% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bristol-Myers Squibb quarterly revenues are $11.2B, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Bristol-Myers Squibb's net income of $2.5B is lower than Eli Lilly and's net income of $2.8B. Notably, Bristol-Myers Squibb's price-to-earnings ratio is 17.67x while Eli Lilly and's PE ratio is 64.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bristol-Myers Squibb is 2.01x versus 14.56x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 21.93% compared to Bristol-Myers Squibb's net margin of -907.48%. Bristol-Myers Squibb's return on equity of 32.01% beat Moderna's return on equity of -29.23%.

Bristol-Myers Squibb has a consensus price target of $57.01, signalling upside risk potential of 20.85%. On the other hand Moderna has an analysts' consensus of $47.59 which suggests that it could grow by 48.44%. Given that Moderna has higher upside potential than Bristol-Myers Squibb, analysts believe Moderna is more attractive than Bristol-Myers Squibb.

Bristol-Myers Squibb has a beta of 0.363, which suggesting that the stock is 63.75% less volatile than S&P 500. In comparison Moderna has a beta of 1.845, suggesting its more volatile than the S&P 500 by 84.505%.

Bristol-Myers Squibb has a quarterly dividend of $0.62 per share corresponding to a yield of 5.22%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bristol-Myers Squibb pays -54.35% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Bristol-Myers Squibb quarterly revenues are $11.2B, which are larger than Moderna quarterly revenues of $107M. Bristol-Myers Squibb's net income of $2.5B is higher than Moderna's net income of -$971M. Notably, Bristol-Myers Squibb's price-to-earnings ratio is 17.67x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bristol-Myers Squibb is 2.01x versus 3.97x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.